Association of pan-immune-inflammation value and atherogenic index of plasma with chronic coronary syndrome in non-alcoholic fatty liver disease patients

非酒精性脂肪肝患者血浆泛免疫炎症值和动脉粥样硬化指数与慢性冠状动脉综合征的相关性

阅读:1

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is linked to a higher risk of cardiovascular disease, particularly chronic coronary syndrome (CCS). However, reliable biomarkers for early CCS risk stratification in NAFLD patients remain lacking. This study aims to assess the pan-immune-inflammation value (PIV) and atherogenic index of plasma (AIP) for CCS in NAFLD patients and to construct a practical tool for personalized risk assessment. METHODS: This retrospective study included 459 NAFLD patients undergoing coronary angiography. Least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression were used to discover independent risk variables for CCS. A nomogram was constructed to quantify CCS risk. Model performance was evaluated by calibration curves, concordance index, and decision curve analysis (DCA). Trend tests assessed the relationship between PIV, AIP quartiles, and CCS risk, while quantile regression analyzed their associations with coronary lesion severity (Gensini scores). RESULTS: Eight independent variables were identified. Elevated lnPIV (OR, 2.195; 95% CI, 1.564-3.125; P< 0.001) and AIP (OR, 4.147; 95% CI, 1.770-10.095; P< 0.001) were strongly associated with CCS. The nomogram demonstrated good discrimination (C-index = 0.782) and calibration. Trend tests revealed a significant positive correlation between lnPIV/AIP quartiles and CCS risk (P for trend< 0.05). Quantile regression further indicated that lnPIV and AIP positively correlated with higher Gensini scores. CONCLUSIONS: lnPIV and AIP are independent biomarkers for CCS in NAFLD patients. The nomogram provides a valuable tool for CCS risk stratification and personalized management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。